Kolon Life Science has secured a manufacturing patent for its cell and gene therapy product TG-C, aimed at treating osteoarthritis, in Singapore. The company plans to expand its rights in Asia while accelerating preparations for the expected topline results from its U.S. Phase 3 clinical trial in July and for FDA approval.
On June 17, Kolon Life Science announced that its patent for a "pharmaceutical composition for the prevention or treatment of osteoarthritis" has been registered in Singapore. This patent covers technology related to reducing cell aggregation during the cell culture process and ensuring stable acquisition of cells of a specific size.
TG-C is a cell and gene therapy administered via injection into the knee joint, developed by mixing allogeneic cartilage-derived chondrocytes with TGF-β1 gene-transduced cells. Kolon Life Science explained that this patent grants them the rights to consistently manage cell characteristics during the manufacturing process.
The patent is already registered in the U.S., South Korea, Japan, and Australia, with applications pending in China and Canada. Kolon Life Science aims to leverage the Singapore registration to further establish its business foundation in Asia.
Lee Han-guk, CEO of Kolon Life Science, stated, "The technological competitiveness of managing cell quality during the TG-C manufacturing process is being recognized internationally," adding, "We will continue preparations for global commercialization."
Kolon TissueGene is currently in the final stages of its U.S. Phase 3 trial, with topline results expected to be released in July.
Additionally, Kolon Life Science recently decided to invest approximately 15 billion won in its wholly-owned subsidiary Kolon Biotech. Kolon Biotech specializes in contract development and manufacturing of cell and gene therapies and was spun off from Kolon Life Science in December 2020. This investment is seen as a step toward commercial production of TG-C.
On June 17, Kolon Life Science announced that its patent for a "pharmaceutical composition for the prevention or treatment of osteoarthritis" has been registered in Singapore. This patent covers technology related to reducing cell aggregation during the cell culture process and ensuring stable acquisition of cells of a specific size.
TG-C is a cell and gene therapy administered via injection into the knee joint, developed by mixing allogeneic cartilage-derived chondrocytes with TGF-β1 gene-transduced cells. Kolon Life Science explained that this patent grants them the rights to consistently manage cell characteristics during the manufacturing process.
The patent is already registered in the U.S., South Korea, Japan, and Australia, with applications pending in China and Canada. Kolon Life Science aims to leverage the Singapore registration to further establish its business foundation in Asia.
Lee Han-guk, CEO of Kolon Life Science, stated, "The technological competitiveness of managing cell quality during the TG-C manufacturing process is being recognized internationally," adding, "We will continue preparations for global commercialization."
Kolon TissueGene is currently in the final stages of its U.S. Phase 3 trial, with topline results expected to be released in July.
Additionally, Kolon Life Science recently decided to invest approximately 15 billion won in its wholly-owned subsidiary Kolon Biotech. Kolon Biotech specializes in contract development and manufacturing of cell and gene therapies and was spun off from Kolon Life Science in December 2020. This investment is seen as a step toward commercial production of TG-C.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.